Amylyx Pharmaceuticals secured approval in Canada on Monday for a new medicine to treat patients with ALS — the same drug that has faced skepticism from regulators in the U.S., where an approval decision is expected in September.
The drug, called Albrioza, is the first new therapy approved for ALS in Canada since 2018. The medicine is also the first to be approved from Amylyx, based in Cambridge, Mass.
“We are excited with Health Canada’s decision to approve Albrioza,” said Justin Klee, co-founder and co-CEO of Amylyx. “We are grateful to the people who participated in our clinical trials, their families, the researchers, and the ALS community for helping to make this milestone happen.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
